Compare Stocks → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:ABCNNYSEAMERICAN:ASTOTCMKTS:ATTBF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCNVIVO CannabisC$1.32+5.6%C$1.32C$0.80▼C$4.06C$256.62MN/A1.51 million shs310,601 shsASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsATTBFAbattis Bioceuticals$0.00$0.00▼$0.00N/AN/A11,650 shsN/A(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCNVIVO Cannabis0.00%0.00%0.00%0.00%0.00%ATTBFAbattis Bioceuticals0.00%0.00%0.00%0.00%0.00%Elon Musk’s Controversial New Project: “Apollo” (Ad)Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCNVIVO CannabisN/AN/AN/AN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCNVIVO CannabisN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCNVIVO CannabisN/AN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCNVIVO CannabisN/AN/A0.00∞N/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/A-$0.16N/AN/AN/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCNVIVO CannabisN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AATTBFAbattis BioceuticalsN/AN/AN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCNVIVO CannabisN/AASTAsterias BiotherapeuticsN/AATTBFAbattis Bioceuticals32.45%Insider OwnershipCompanyInsider OwnershipABCNVIVO CannabisN/AASTAsterias BiotherapeuticsN/AATTBFAbattis BioceuticalsN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABCNVIVO CannabisN/A194.41 millionN/ANot OptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableATTBFAbattis BioceuticalsN/AN/AN/ANot OptionableAST, ATTBF, ABCN, ABZA, and AHZ HeadlinesSourceHeadlineAbattis Bioceuticals Corp ATTBFmorningstar.com - November 11 at 8:24 AMIllumina Aktiefinanzen100.de - June 28 at 8:57 PMHow a Jungle Prison Became a Famous Spaceportsmithsonianmag.com - June 24 at 12:03 AMIsotretinoin Price of 93 Brandsmedindia.net - May 9 at 12:56 PMIvermectin Price of 102 Brandsmedindia.net - April 20 at 12:36 PMAbattis Bioceuticals Corp ATTBF Sustainabilitymorningstar.com - September 9 at 10:20 PMWhen Will New Jersey's Marijuana Sales Begin? What's Next After Yet Another Delay?benzinga.com - March 27 at 6:36 PMCannabis Payments Co Launches Women In Finance & Technology Scholarshipbenzinga.com - March 26 at 8:52 PMCharlotte's Web Q4 Revenue Up 5% QoQ, Adjusted EBITDA Loss Improves By $5Mbenzinga.com - March 25 at 11:58 PMFederal Marijuana Cases Drop Again In 2021 As More States Legalizebenzinga.com - March 20 at 10:08 PMSchwazze Common Shares Will Trade On NEO Exchange Under Symbol 'SHWZ' In Late Marchbenzinga.com - March 20 at 10:08 PMMDXclusive Launches Lab-Tested Topical And Sublingual CBD Productsbenzinga.com - March 9 at 9:22 PMThe Perfect CBD To THC Ratio? New Study Says 1 To 1 Is The Best Ratio For Therapeutic Effectsbenzinga.com - March 6 at 7:27 PMMost D.C. Workers To Avoid Pre-Employment Marijuana Testing Under New Billbenzinga.com - March 5 at 10:25 PMBDSA Report: Global Cannabis Sales Will Jump 22% In 2022, Grow To $61B By 2026benzinga.com - March 3 at 8:58 PMTrulieve Files Resale Registration With SEC For Subordinate Voting Shares Of 2021 Acquisitionsbenzinga.com - January 26 at 12:56 AMLatest Issue Of Psychedelics Mag DoubleBlind Plays With The Tension Between Old And Newbenzinga.com - December 22 at 6:09 PMAbattis Bioceuticals Dividend Per Share (TTM)ycharts.com - December 18 at 12:59 AMAbattis Bioceuticals EPS Diluted (5 Year Growth)ycharts.com - December 18 at 12:59 AMMicah Tapman Of BDSA Lays Out Cannabis Data In The Northeastbenzinga.com - October 18 at 7:08 PMApple's Cannabis iPhone App Is Benefiting Businesses And Consumers, Where's Google Play Store?benzinga.com - September 3 at 9:10 PMPanama Is Close To Legalizing Medicinal Cannabisbenzinga.com - August 31 at 6:25 PMEXCLUSIVE: Healthcare Attorney Brian Rath Discusses Medical Marijuana In Nursing Homes & Assisted Living, Legal? It's Complicatedbenzinga.com - August 18 at 3:50 AMNew MarketBeat Followers Over TimeTop HeadlinesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentPalantir Technologies: Bearish Sentiment, Bullish Chart SignalsMarch 27, 2024 7:30 AMView Palantir Technologies: Bearish Sentiment, Bullish Chart SignalsDisney Stock Catches 3 Upgrades In a Single WeekMarch 28, 2024 10:27 AMView Disney Stock Catches 3 Upgrades In a Single WeekBreakout Alert: Coinbase's Consolidation Is About To EndApril 12, 2024 9:45 AMView Breakout Alert: Coinbase's Consolidation Is About To EndBuy the Dip in Netflix Stock, It Won’t Last LongApril 19, 2024 8:32 AMView Buy the Dip in Netflix Stock, It Won’t Last LongAll Headlines Company DescriptionsVIVO CannabisCVE:ABCNABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.Asterias BiotherapeuticsNYSEAMERICAN:ASTAsterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.Abattis BioceuticalsOTCMKTS:ATTBFAbattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.